Robert L. Myette

Dr. Robert L. Myette


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SESean P. Ebert
Sean P. Ebert
BWBryan Wetzel
Bryan Wetzel
RMRobert L. Myette
Robert L. Myette
GCGwenaëlle Conseil
Gwenaëlle Conseil
SCSusan Cole
Susan Cole
MDMichael R. Detty
Michael R. Detty

29 January 2020 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
TMThalia Medeiros
Thalia Medeiros
RMRobert L. Myette
Robert L. Myette
JAJorge Reis Almeida
Jorge Reis Almeida
ASAndrea Alice Silva
Andrea Alice Silva
DBDylan Burger
Dylan Burger
Extracellular vesicles (EVs) are important mediators of intercellular communication. Since EVs are also released during pathological conditions, there has been considerable interest in their potential as sensitive biomarkers of cellular stress and/or injury. In the context of kidney disease, urinary EVs are promising indicators of glomerular and tubular damage. In the present review we discuss the role of urinary EVs in kidney health and disease. Our focus is to explore urinary large EVs (lEVs, often referred to as microparticles or microvesicles) as direct and noninvasive early biomarkers of renal injury. In this regard, studies have been demonstrating altered levels of urinary lEVs, especially podocyte-derived lEVs, preceding the decrease of renal function assessed by classical markers. In addition, we discuss the role of small EVs (sEVs, often referred to as exosomes) and their contents in kidney pathophysiology. Even though results concerning the production of sEVs during diseased conditions are varied, there has been a consensus on the importance of urinary sEV content assessment in kidney disease. These mediators, including EV-released miRNAs and mRNAs, are responsible for EV-mediated signaling in the regulation of renal cellular homeostasis, pathogenesis and regeneration. Finally, steps necessary for the validation of EVs as reliable markers will be discussed.

29 April 2023 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
RMRobert L. Myette
Robert L. Myette
FXFengxia Xiao
Fengxia Xiao
PGPavel Geier
Pavel Geier
JFJanusz Feber
Janusz Feber
DBDylan Burger
Dylan Burger
CKChris Kennedy
Chris Kennedy
Robert L Myette, Fengxia Xiao, Pavel Geier, Janusz Feber, Dylan Burger, Christopher R J Kennedy; Urinary podocyte-derived large extracellular vesicles are incre

1 June 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
RMRobert L. Myette
Robert L. Myette
GCGwenaëlle Conseil
Gwenaëlle Conseil
SESean P. Ebert
Sean P. Ebert
BWBryan Wetzel
Bryan Wetzel
MDMichael R. Detty
Michael R. Detty
SCSusan Cole
Susan Cole
Multidrug resistance proteins (MRPs) mediate the ATP-dependent efflux of structurally diverse compounds, including anticancer drugs and physiologic organic anions. Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [3H]estradiol glucuronide (E217βG; a prototypical MRP substrate) into MRP-enriched inside-out membrane vesicles. Additionally, some CGPs were tested in intact transfected cells using a calcein efflux assay. Sixteen of 34 CGPs inhibited MRP1-mediated E217βG uptake by >50% (IC50 values: 0.7–7.6 µM). Of 9 CGPs with IC50 values ≤2 µM, two belonged to class I, two to class III, and five to class V. When tested in the intact cells, only 4 of 16 CGPs (at 10 µM) inhibited MRP1-mediated calcein efflux by >50% (III-1, V-3, V-4, V-6), whereas a fifth (I-5) inhibited efflux by just 23%. These five CGPs also inhibited [3H]E217βG uptake by MRP4. In contrast, their effects on MRP2 varied, with two (V-4, V-6) inhibiting E217βG transport (IC50 values: 2.0 and 9.2 µM) and two (V-3, III-1) stimulating transport (>2-fold), whereas CGP I-5 had no effect. Strikingly, although V-3 and V-4 had opposite effects on MRP2 activity, they are structurally identical except for their chalcogen atom (Se versus Te). This study is the first to identify class V CGPs, with their distinctive methine or trimethine linkage between two disubstituted pyrylium moieties, as a particularly potent class of MRP modulators, and to show that, within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.

1 January 2024 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
RMRobert L. Myette
Robert L. Myette
CLCaroline Lamarche
Caroline Lamarche
AOAyodele Odutayo
Ayodele Odutayo
NVNancy Verdin
Nancy Verdin
MCMark Canney
Mark Canney
Purpose of review: Cardiovascular (CV) disease is a major cause of morbidity and mortality for patients with glomerular disease. Despite the fact that mechanisms underpinning CV disease risk in this population are likely distinct from other forms of kidney disease, treatment and preventive strategies tend to be extrapolated from studies of patients with undifferentiated chronic kidney disease (CKD). There is an unmet need to delineate the pathophysiology of CV disease in patients with glomerular disease, establish unique risk factors, and identify novel therapeutic targets for disease prevention. The aims of this narrative review are to summarize the existing knowledge regarding the epidemiology, molecular mechanisms, and management of CV disease in patients with common glomerular disease, highlight the patient perspective, and propose specific areas for future study. Sources of information: The literature for this narrative review was accessed using common research search engines, including PubMed, PubMed Central, Medline, and Google Scholar. Information for the patient perspective section was collected through iterative discussions with a patient partner. Methods: We reviewed the epidemiology, molecular mechanisms of disease, management approaches, and the patient perspective in relation to CV disease in patients with glomerulopathies. Throughout, we have highlighted the current knowledge and have discussed future research approaches, both clinical and translational, while integrating the patient perspective. Key findings: Patients with glomerular disease have significant CV disease risk driven by multifactorial, molecular mechanisms originating from their glomerular disease but complicated by existing comorbidities, kidney disease, and medication side effects. The current approach to risk stratification and treatment relies heavily on existing data from CKD patients, but this may not always be appropriate given the unique pathophysiology and mechanisms associated with CV disease risk in patients with glomerular disease. We highlight the need for ongoing glomerular disease-focused studies aimed to better delineate CV disease risk, while integrating the patient perspective. Limitations: This is a narrative review and does not represent a comprehensive and systematic review of the literature.

27 September 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
RMRobert L. Myette
Robert L. Myette
Mayra Trentin SonodaMayra Trentin Sonoda
Mayra Trentin Sonoda
CLChloé Landry
Chloé Landry
CHChet E. Holterman
Chet E. Holterman
TLTony Lin
Tony Lin
CKChristopher R.J. Kennedy
Christopher R.J. Kennedy
Podocytes possess immune system components allowing for a variety of innate responses to endogenous and exogenous stimuli. Recently, several groups have linked inappropriate innate immune signaling to podocyte injury, particularly chronic, sustained injury; however, the immune capabilities of podocytes have not been fully elucidated. Damage-associated molecular patterns (DAMPs) are endogenous danger molecules released from damaged cells, including podocytes, and can elicit an inflammatory response and recruit immune cells to areas of injury. This is performed through binding to pattern recognition receptors. Believed largely to be protective and responsive to injury or infection, recent evidence suggests signaling through DAMP pathways can aggravate and promote chronic diseases already associated with inflammation. The purpose of this narrative review was to highlight current knowledge with respect to specific podocyte DAMPs and pattern recognition receptors and to provide insight into ongoing work and possible future research avenues to advance our understanding of podocyte immune mechanisms.